Tirzepatide received FDA approval as Mounjaro in May 2022 for type 2 diabetes mellitus and as Zepbound in November 2023 for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
These markings may appear as though they can be scrubbed away, but you can't remove them
Aging is the culmination of all the changes that occur to people through time, including psychological, social, and physical changes
Carbohydrates also stimulate GLP-1 when they reach the small intestine, helping the body release insulin, regulate blood sugar, and slow digestion
751 obese adults without diabetes were randomized to maximum tolerated doses of tirzepatide versus semaglutide over 72 weeks
2 In a large, randomized, multicenter trial, patients were assigned to an intensive lifestyle intervention group or to a diabetes support and education group